Home - TG Therapeutics
LATEST NEWS TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
TG Therapeutics Reports Third Quarter 2024 Financial Results and …
Nov 4, 2024 · TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases.
TG Therapeutics Inc (TGTX) Q3 2024 Earnings Call Highlights: …
6 days ago · TG Therapeutics Inc (NASDAQ:TGTX) reported strong third-quarter US net sales of $83.3 million, reflecting approximately 15% quarter-over-quarter growth and over 230% growth from the same quarter ...
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early …
5 days ago · TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. Read more here.
TG Therapeutics Boosts Revenue Outlook Amidst Growth
6 days ago · In their third quarter 2024 financial report, TG Therapeutics reported significant growth in BRIUMVI sales, achieving $83.3 million in U.S. net revenue, a 15% increase from the previous quarter ...
TG Therapeutics: Q3 Earnings Snapshot - Yahoo Finance
Nov 4, 2024 · TGTX. MORRISVILLE, N.Y. (AP) — MORRISVILLE, N.Y. (AP) — TG Therapeutics Inc. (TGTX) on Monday reported third-quarter earnings of $3.9 million. On a per-share basis, the Morrisville, New York ...
Press Releases - TG Therapeutics, Inc.
Nov 1, 2024 · NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis
TG Therapeutics Provides Business Update and Reports First …
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2024, along with recent company developments.
TG Therapeutics Announces FDA Approval of BRIUMVI™ …
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the U.S. Food and Drug Administration (FDA) has approved BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary ...
TG Therapeutics to Host Conference Call on Third Quarter 2024 …
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for ...